CervoMed Reports $7.7 Million Net Loss in Q3 2025, Plans Phase 3 Trial for Neflamapimod

CervoMed Inc., formerly known as Diffusion Pharmaceuticals Inc., reported its financial results for the third quarter of 2025, revealing a net loss of $7.7 million, a 63% increase from the $4.8 million loss recorded in the same period last year. For the nine months ending September 30, 2025, the company reported a net loss of $18.9 million, compared to $9.6 million for the same period in 2024. The increase in losses is attributed to rising operating expenses, which totaled $24 million for the nine months, up 29% from $18.6 million in the prior year. The company’s grant revenue also saw a significant decline, falling to $0.3 million in Q3 2025 from $1.9 million in Q3 2024, primarily due to the transition from the Initial Phase to the Extension Phase of the RewinD-LB Trial.

CervoMed's operating expenses for the third quarter included $6 million in research and development, an 18% increase from the previous year, driven by higher personnel costs and increased activities related to the company's clinical trials. General and administrative expenses also rose to $2.3 million, a 5% increase year-over-year. The company’s accumulated deficit reached $89.6 million as of September 30, 2025, reflecting its ongoing investment in clinical development without any product revenue to date.

Strategically, CervoMed has made significant advancements in its clinical programs, particularly with its lead drug candidate, neflamapimod, which targets dementia with Lewy bodies (DLB). The company recently completed the RewinD-LB Trial, a Phase 2b study funded primarily by a $21.3 million grant from the National Institute on Aging (NIA). The trial's results indicated statistically significant improvements in cognitive function, supporting the drug's potential as a treatment for DLB. Following these results, CervoMed plans to initiate a Phase 3 clinical trial in 2026, focusing on patients without Alzheimer's disease co-pathology.

As of September 30, 2025, CervoMed reported cash and cash equivalents of approximately $9.4 million, alongside marketable securities totaling $17.9 million, bringing total current assets to $30.6 million. However, the company expressed concerns regarding its liquidity, stating that its existing resources may not be sufficient to fund operations for the next twelve months. CervoMed is actively seeking additional financing through equity offerings and collaborations to support its ongoing clinical development and operational needs.

Looking ahead, CervoMed anticipates continued increases in research and development expenses as it advances neflamapimod through clinical trials and seeks regulatory approval. The company remains focused on addressing the material weaknesses in its internal controls over financial reporting, which were identified during its recent audits. Despite these challenges, CervoMed is committed to its mission of developing innovative treatments for age-related brain disorders and is optimistic about the potential of neflamapimod in improving patient outcomes.